Mangoceuticals (NASDAQ: MGRX) Q1 2026 shows small sales, heavy loss and thin cash
Mangoceuticals Inc. reported a Q1 2026 net loss of $3.4 million on revenues of $67,864, down from the prior year, with significant spending on operations and stock-based compensation. The company's cash and cash equivalents dwindled to $174,562, highlighting severe liquidity concerns and the need for new financing. Intangible assets, primarily patents and licenses, comprise the majority of the company's total assets, while liabilities remain relatively modest.
FEB 20·Bitget▲
Mangoceuticals Stock Surges On Early Success Of Subscription TRT Model
Mangoceuticals, Inc. (NASDAQ:MGRX) shares are trading higher due to the early success of its new all-inclusive injectable Testosterone Replacement Therapy (TRT) treatment program. The company reported a 336% increase in month-over-month sales for its TRT program since mid-December and a 54% reduction in customer acquisition costs. This $99-per-month program, delivered via telehealth, is expected to be Mangoceuticals' primary growth driver.
FEB 20·Meyka▲
MGRX (Mangoceuticals, Inc., NASDAQ) up 50.75% intraday 20 Feb 2026: TRT sales drive heavy volume
Mangoceuticals, Inc. (MGRX) experienced a significant 50.75% intraday surge on February 20, 2026, driven by strong initial sales results from its $99 injectable TRT program. The company reported 336% month-over-month sales growth and a 54% reduction in customer acquisition cost, leading to a massive volume spike of nearly 300 million shares. While strong TRT sales propelled the stock, Meyka AI's model projects a 12-month fair value of USD 0.26, indicating potential downside due to ongoing net losses and liquidity risks.
